
ARTV Stock Forecast & Price Target
ARTV Analyst Ratings
Bulls say
Artiva Biotherapeutics Inc. is positively positioned due to its robust pipeline of off-the-shelf NK cell therapies, particularly the AlloNK candidate, which is designed to enhance the effectiveness of monoclonal antibodies in treating hematologic malignancies. The company has reported strong enrollment figures, with over a dozen patients in August and expectations for more than 20 by November, indicating a favorable safety profile and potential for durable clinical remissions. Additionally, the anticipated release of significant clinical response data in the first half of 2026 further supports a bullish outlook, suggesting the potential for substantial appreciation in the stock as these data sets are revealed.
Bears say
Artiva Biotherapeutics faces a negative outlook primarily due to the potential failure of its AlloNK therapy to demonstrate adequate efficacy and safety, with data expected in the first half of 2025 suggesting a decline in the probability of success to 10%. This failure could significantly affect the company's valuation, implying an approximate 25% downside to its base case scenario. Additionally, there are concerns about the overall viability of Artiva's NK cell therapy platform, which could hinder the company's ability to generate further successful clinical candidates.
This aggregate rating is based on analysts' research of Artiva Biotherapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
ARTV Analyst Forecast & Price Prediction
Start investing in ARTV
Order type
Buy in
Order amount
Est. shares
0 shares